Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Pulmonary Circulation Pub Date : 2024-04-15 DOI:10.1002/pul2.12326

Harrison W. Farber, Hayley D. Germack, Nicole S. Croteau, Jason C. Simeone, Fei Tang, Carly J. Paoli, Gurinderpal Doad, Sumeet Panjabi, Teresa De Marco

引用次数: 0

Abstract

Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.

查看原文本刊更多论文

美国肺动脉高压患者中断治疗的相关因素

有关导致肺动脉高压（PAH）治疗中断的因素的信息十分有限。这项研究分析了 12902 名新的 PAH 药物使用者，以确定中断治疗的预测因素。由经认证的肺动脉高压中心进行治疗和使用不同类别的 PAH 药物进行联合治疗导致中断治疗的可能性较小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonary Circulation Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.20

自引率

11.50%

发文量

153

审稿时长

15 weeks

期刊介绍： Pulmonary Circulation''s main goal is to encourage basic, translational, and clinical research by investigators, physician-scientists, and clinicans, in the hope of increasing survival rates for pulmonary hypertension and other pulmonary vascular diseases worldwide, and developing new therapeutic approaches for the diseases. Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a wide readership of specialists in order to improve patient care and treatment outcomes.